Steward Partners Investment Advisory’s abrdn Life Sciences Investors HQL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $884K | Buy |
54,313
+7,127
| +15% | +$119K | ﹤0.01% | 1233 |
|
|
2025
Q4 | $792K | Buy |
47,186
+25,770
| +120% | +$433K | ﹤0.01% | 1185 |
|
|
2025
Q3 | $332K | Buy |
21,416
+8,208
| +62% | +$112K | ﹤0.01% | 1599 |
|
|
2025
Q2 | $169K | Hold |
13,208
| – | – | ﹤0.01% | 1836 |
|
|
2025
Q1 | $168K | Buy |
13,208
+8,348
| +172% | +$113K | ﹤0.01% | 1737 |
|
|
2024
Q4 | $63.8K | Buy |
4,860
+3,847
| +380% | +$55.5K | ﹤0.01% | 2209 |
|
|
2024
Q3 | $15.3K | Sell |
1,013
-1,056
| -51% | -$16K | ﹤0.01% | 2769 |
|
|
2024
Q2 | $29.3K | Buy |
2,069
+69
| +3% | +$933 | ﹤0.01% | 2356 |
|
|
2024
Q1 | $27.3K | Buy |
2,000
+97
| +5% | +$1.34K | ﹤0.01% | 2383 |
|
|
2023
Q4 | $25.6K | Buy |
1,903
+343
| +22% | +$4.22K | ﹤0.01% | 2293 |
|
|
2023
Q3 | $19.5K | Buy |
1,560
+38
| +2% | +$500 | ﹤0.01% | 2321 |
|
|
2023
Q2 | $20.6K | Buy |
1,522
+33
| +2% | +$455 | ﹤0.01% | 2273 |
|
|
2023
Q1 | $20.7K | Buy |
1,489
+35
| +2% | +$500 | ﹤0.01% | 2237 |
|
|
2022
Q4 | $20.7K | Buy |
1,454
+29
| +2% | +$420 | ﹤0.01% | 2221 |
|
|
2022
Q3 | $19K | Buy |
1,425
+4
| +0.3% | +$60 | ﹤0.01% | 2245 |
|
|
2022
Q2 | $20K | Buy |
1,421
+34
| +2% | +$514 | ﹤0.01% | 2220 |
|
|
2022
Q1 | $23K | Buy |
1,387
+592
| +74% | +$10.2K | ﹤0.01% | 2295 |
|
|
2021
Q4 | $15K | Buy |
795
+16
| +2% | +$322 | ﹤0.01% | 2437 |
|
|
2021
Q3 | $16K | Buy |
779
+15
| +2% | +$321 | ﹤0.01% | 2415 |
|
|
2021
Q2 | $16K | Sell |
764
-1,123
| -60% | -$22.7K | ﹤0.01% | 5393 |
|
|
2021
Q1 | $37.2K | Buy |
1,887
+39
| +2% | +$804 | ﹤0.01% | 2141 |
|
|
2020
Q4 | $37K | Buy |
1,848
+34
| +2% | +$628 | ﹤0.01% | 1809 |
|
|
2020
Q3 | $32K | Buy |
1,814
+41
| +2% | +$734 | ﹤0.01% | 1696 |
|
|
2020
Q2 | $32K | Buy |
1,773
+31
| +2% | +$531 | ﹤0.01% | 1592 |
|
|
2020
Q1 | $26K | Buy |
1,742
+51
| +3% | +$835 | ﹤0.01% | 1507 |
|
|
2019
Q4 | $29K | Buy |
1,691
+29
| +2% | +$476 | ﹤0.01% | 1637 |
|
|
2019
Q3 | $25K | Sell |
1,662
-1,145
| -41% | -$18.3K | ﹤0.01% | 1643 |
|
|
2019
Q2 | $47K | Buy |
+2,807
| New | +$46.2K | ﹤0.01% | 1358 |
|
|
2018
Q4 | – | Sell |
-3,443
| Closed | -$70K | – | 1367 |
|
|
2018
Q3 | $70K | Buy |
3,443
+65
| +2% | +$1.29K | ﹤0.01% | 1057 |
|
|
2018
Q2 | $63K | Buy |
3,378
+79
| +2% | +$1.49K | ﹤0.01% | 1007 |
|
|
2018
Q1 | $63K | Sell |
3,299
-975
| -23% | -$19.5K | ﹤0.01% | 920 |
|
|
2017
Q4 | $83K | Buy |
4,274
+169
| +4% | +$3.38K | 0.01% | 685 |
|
|
2017
Q3 | $88K | Buy |
4,105
+3,280
| +398% | +$69.7K | 0.01% | 563 |
|
|
2017
Q2 | $17K | Buy |
+825
| New | +$16.7K | ﹤0.01% | 910 |
|
Other funds holding HQL
SCM
PCM
NIM
FHA
RCM
Steward Partners Investment Advisory's HQL Position: Q1 2026 in Review
Steward Partners Investment Advisory increased its abrdn Life Sciences Investors (HQL) stake by 15% in Q1 2026, buying an estimated $119K and bringing the position to 54,313 shares worth $884K. The position accounts for ﹤0.01% of the portfolio, ranked #1233.
Steward Partners Investment Advisory first reported a position in HQL in Q2 2017 and has held it in 34 quarters since. 86 funds tracked by Wall St. Rank hold HQL as of Q1 2026.
- Steward Partners Investment Advisory held 54,313 shares of abrdn Life Sciences Investors worth $884K as of Q1 2026.
- Steward Partners Investment Advisory bought 7,127 abrdn Life Sciences Investors shares in Q1 2026, an estimated $119K.
- abrdn Life Sciences Investors made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q1 2026, its #1233 holding.
- Steward Partners Investment Advisory first reported a position in abrdn Life Sciences Investors in Q2 2017 and has held it in 34 quarters since.
- 86 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2026.
Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.